文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

多拉韦林对体外选择性药物压力下携带NRTI和NNRTI突变HIV-1病毒的应答

Doravirine responses to HIV-1 viruses bearing mutations to NRTIs and NNRTIs under in vitro selective drug pressure.
PubMed 文献 · J Antimicrob Chemother · 2023-01-01

本研究通过体外药物选择实验,将6株野生型临床分离株和6株携带常见NRTI及NNRTI耐药相关突变的病毒在递增浓度的多拉韦林、多拉韦林/伊斯拉曲韦、多拉韦林/拉米夫定和利匹韦林中进行连续传代24周。结果显示多拉韦林对携带NRTI和NNRTI突变的病毒具有有利的耐药谱,与伊斯拉曲韦或拉米夫定联用可减弱NNRTI耐药突变的出现。

要点

  • 多拉韦林压力下野生型病毒8周出现V108I或V106A/I/M突变,耐药约2倍。
  • 24周后累积3-6个次要突变导致对多拉韦林高水平耐药(>100倍)。
  • 携带这些多拉韦林突变的病毒仍对利匹韦林和依非韦伦敏感。

核心结论

  • 多拉韦林对携带NRTI和NNRTI耐药相关突变的病毒显示出有利的耐药谱。
  • 多拉韦林的高耐药屏障与伊斯拉曲韦的长细胞内半衰期可能为长效治疗方案提供机会。

研究设计与样本

  • 体外药物选择研究:6株野生型临床分离株和6株携带常见NRTI及NNRTI耐药相关突变的病毒,在递增浓度的多拉韦林、多拉韦林/伊斯拉曲韦、多拉韦林/拉米夫定和利匹韦林中进行连续传代24周。

主要发现

  • 野生型病毒在多拉韦林压力下8周出现V108I或V106A/I/M突变,导致低水平(约2倍)耐药。
  • 24周后累积3至6个次要突变(包括F227L、M230L、L234I和/或Y318),导致对多拉韦林高水平(>100倍)耐药。
  • 携带这些多拉韦林耐药突变的病毒仍对利匹韦林和依非韦伦敏感。
  • 利匹韦林选择获得E138K、L100I和/或K101E,导致对所有NNRTI >50倍交叉耐药。
  • 多拉韦林对携带常见NRTI和NNRTI耐药突变病毒的选择显示耐药突变获得较野生型病毒延迟;多拉韦林与伊斯拉曲韦或拉米夫定联用减弱了NNRTI耐药突变的出现。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The NNRTI doravirine has been recently approved for the first-line treatment of HIV-infected patients, eliciting favourable responses against viruses bearing the K103N, Y181C and G190A mutations. This study used in vitro drug selections to elaborate the breadth of doravirine responses against viruses bearing NNRTI and NRTI resistance-associated mutations (RAMs). METHODS: WT clinical isolates (n = 6) and viruses harbouring common NRTI and NNRTI RAMs (n = 6) were serially passaged in escalating concentrations of doravirine, doravirine/islatravir, doravirine/lamivudine and rilpivirine over 24 weeks. Genotypic analysis ascertained the appearance and accumulation of NNRTI RAMs. Phenotypic drug susceptibility assays assessed resistance conferred by acquired NNRTI RAMs. RESULTS: For WT viruses, doravirine pressure led to the appearance of V108I or V106A/I/M RAMs after 8 weeks, conferring low-level (∼2-fold) resistance. After 24 weeks, the accumulation of three to six secondary RAMs, including F227L, M230L, L234I and/or Y318, resulted in high-level (>100-fold) resistance to doravirine. Notably, viruses with these doravirine RAMs remained susceptible to rilpivirine and efavirenz. This contrasted with rilpivirine where acquisition of E138K, L100I and/or K101E resulted in >50-fold cross-resistance to all NNRTIs. Doravirine selection of viruses bearing common NRTI and NNRTI RAMs showed delayed acquisition of RAMs compared with WT virus. Pairing doravirine with islatravir or lamivudine attenuated the development of NNRTI RAMs. CONCLUSIONS: Doravirine showed favourable resistance profiles against viruses harbouring NRTI and NNRTI RAMs. The high barrier to resistance to doravirine coupled with the long intracellular half-life of islatravir may provide the opportunity for long-acting treatment options.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Brenner BG, Oliveira M, Ibanescu RI, et al. Doravirine responses to HIV-1 viruses bearing mutations to NRTIs and NNRTIs under in vitro selective drug pressure. J Antimicrob Chemother. 2023. PMID: 37303226. doi:10.1093/jac/dkad184

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。